The PALB2 gene is a strong candidate for clinical testing in BRCA1 and BRCA2 negative hereditary breast cancer.
Janatova M, Kleibl Z, Stribrna J, et al.
Cancer Epidemiol Biomarkers Prev. 2013 Oct 17. [Epub ahead of print]
Clinical Implementation of Germline Cancer Pharmacogenetic Variants during the Next-Generation Sequencing Era.
Gillis NK, Patel JN, Innocenti F.
Clin Pharmacol Ther. 2013 Oct 17. doi: 10.1038/clpt.2013.214. [Epub ahead of print]
Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer.
Yamamura A, Miura K, Karasawa H, et al.
Biochem Biophys Res Commun. 2013 Oct 14. [Epub ahead of print]
Translating pharmacogenomics discoveries into the clinic: an implementation framework.
Huang RS, Gamazon ER.
Genome Med. 2013 Oct 18;5(10):94. [Epub ahead of print]
Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer.
Chretien AS, Harlé A, Meyer-Lefebvre M, et al.
Cancer Med. 2013 Feb;2(1):11-20. [Epub ahead of print]
Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib.
Dai J, Kong Y, Si L, et al.
Clin Cancer Res. 2013 Oct 16. [Epub ahead of print]
The effect of VEGF targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.
Sharpe K, Stewart GD, Mackay A, et al.
Clin Cancer Res. 2013 Oct 15. [Epub ahead of print]
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
Savas P, Hughes B, Solomon B.
J Thorac Dis. 2013 Oct;5(Suppl 5):S579-S592.
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL inhibition by Suppressing MCL-1.
Faber AC, Coffee EM, Costa C, et al.
Cancer Discov. 2013 Oct 25. [Epub ahead of print]
The Characteristics of Breast Cancer Subtypes: Implications for Treatment Guidelines and Individualized Treatment Strategies in China.
Zheng S, Song QK, Ren Y, et al.
Appl Immunohistochem Mol Morphol. 2013 Oct 24. [Epub ahead of print]
Drugs, Genes and the Blues: Pharmacogenetics of the Antidepressant Response from Mouse to Man.
O'Leary OF, O'Brien FE, O'Connor RM, Cryan JF.
Pharmacol Biochem Behav. 2013 Oct 23. [Epub ahead of print]
Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.
Patel S.
Curr Oncol Rep. 2013 Aug;15(4):386-95.
Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas.
Raghav KP, Shetty AV, Kazmi SM, et al.
Oncologist. 2013 Oct 22. [Epub ahead of print]
Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: Update and report from a pharmacogenetic service clinic.
Müller DJ, Kekin I, Kao AC, Brandl EJ.
Int Rev Psychiatry. 2013 Oct;25(5):554-71.